Cell type-specific analyses for identifying prostate cancer biomarkers
- PMID: 16480670
- DOI: 10.1007/s11934-006-0039-4
Cell type-specific analyses for identifying prostate cancer biomarkers
Abstract
Cancers of the prostate contribute substantial morbidity and mortality to the male population. The correlation of prostate cancer incidence with aging suggests that the disease burden associated with prostate carcinoma will increase dramatically over the next several decades. Despite the large number of fatalities directly linked to prostate cancer, most men harboring the disease will die of other causes. This fact poses substantial dilemmas for screening programs designed to diagnose cancers at an early stage, as the optimal approach also would provide guidance as to which cancers could or should be observed, versus those malignancies that require curative therapy, and whether localized treatments are sufficient or if additional systemic interventions are indicated. To address these issues, substantial resources have been focused on the identification of biomarkers capable of specifically and sensitively diagnosing prostate cancers and providing prognostic information. However, the discovery and use of biomarkers must contend with the complexity and heterogeneity of body fluids and tissues. This review describes approaches that use cell type-specific analysis methods to identify cancer-associated features with the potential of distinguishing individuals with cancer of the prostate.
Similar articles
-
Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.Dis Markers. 2004;20(2):117-28. doi: 10.1155/2004/509276. Dis Markers. 2004. PMID: 15322319 Free PMC article. Review.
-
The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.Cancer. 1994 Dec 1;74(11):2991-5. doi: 10.1002/1097-0142(19941201)74:11<2991::aid-cncr2820741116>3.0.co;2-r. Cancer. 1994. PMID: 7525040
-
Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].Urol Oncol. 2014 Feb;32(2):208-9. doi: 10.1016/j.urolonc.2013.08.023. Urol Oncol. 2014. PMID: 24445289
-
[New biomarkers in prostate cancer].Praxis (Bern 1994). 2012 Jan 18;101(2):115-21. doi: 10.1024/1661-8157/a000819. Praxis (Bern 1994). 2012. PMID: 22252593 Review. German.
-
Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.Eur Urol. 2021 Jan;79(1):141-149. doi: 10.1016/j.eururo.2020.09.003. Epub 2020 Nov 2. Eur Urol. 2021. PMID: 33148472
Cited by
-
Role of p38 MAP Kinase Signal Transduction in Solid Tumors.Genes Cancer. 2013 Sep;4(9-10):342-59. doi: 10.1177/1947601913507951. Genes Cancer. 2013. PMID: 24349632 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical